Find a Clinical Trial by Adult Cancer Type

Adult Cancers
Childhood Cancers
Doctor
Drug
Phase

Back to Adult Cancers

Cancer Type: Pancreas

34 protocol(s) meet the specified criteria. Please click on the protocol number to get more information about the trial.

Doctor	Protocol No.	Title
Hendifar, Andrew	HALO-109-301	HALO-109-301:A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma (IRB#44206)
Hendifar, Andrew	EA2161	EA2161: A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET) (IRB#49004)
Hendifar, Andrew	IIT2016-07-HENDIFAR-ONFX	IIT2016-07-Hendifar-OnFx: A Phase I study of onivyde (MM-398), 5-fluorouracil/folinic acid in combination with xilonix(TM) for advanced pancreatic cancer patients with cachexia (ONFX) (IRB#46855)
Hendifar, Andrew	IIT2014-03-HENDIFAR-PNCX1	IIT2014-03-Hendifar-PanCax: Enteral Feeding for Pancreatic Cancer Cachexia A Longitudinal, Single Institution Study of Enteral Feeding in Advanced Pancreatic Cancer Patients (IRB#38239)
Lo, Simon	NANOPAC-2016-05	NANOPAC-2016-05: Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac in Subjects with Locally Advanced Pancreatic Adenocarcinoma (IRB#49989)
Pandol, Stephen	IIT2017-06-PANDOL-PDAC	Pancreatic Adenocarcinoma Tests (IRB#48493)
Tuli, Richard	IIT2016-01-TULI-DURVARAD	A Phase I/II Study of Durvalumab (MEDI-4736) and Stereotactive Ablative Body Radiotherapy in Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (IRB#48449)
Tuli, Richard	ONCOPAC1	OncoPaC‐1: An open label, single arm pilot study of OncoSil, administered to subjects with unresectable locally advanced pancreatic adenocarcinoma, given in combination with gemcitabine or gemcitabine+nab‐paclitaxel chemotherapies (IRB #49148)
Asher, Arash	IIT2015-21-ASHER-GRACE	A Randomized Controlled Trial to Strengthen Existential Resiliency among Women with Metastatic Cancer (IRB#43233)
Balmanoukian, Ani	INCB24360-208	A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208) (IRB#50959)
Balmanoukian, Ani	GO39733	GO39733 : A phase IA/IB open-label, dose-escalation study of the safety and pharmacokinetics of RO7198457 as a single agent and in combination with atezolizumab in patients with locally advanced or metastatic tumors (IRB#49235)
Boasberg, Peter D	4020-01-001	4020-01-001: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (IRB#49142)
Goodman, Marc	IIT2016-12-GOODMAN-NWUPAN	Statin Therapy to Reduce the Risk of Recurrent Pancreatitis (IRB#45009)
Hakimian, Behrooz	NG-BSP-600-001	Evaluation of the CytoRADxTM System as a Biodosimeter with Human Subjects Receiving Radiation Therapy (IRB#49276)
Hamid, Omid	INCAGN01949-201	A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (IRB#49356)
Hamid, Omid	INCAGN1876-201	INCAGN 1876-201: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (IRB#47508)
Hamid, Omid	INCAGN1876-101	A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors (IRB#43777)
Hamid, Omid	R3767-ONC-1613	R3767-ONC-1613: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies (IRB#48031)
Hamid, Omid	CMIW815X2102J	CMIW815X2102J: A Phase Ib, open label, multicenter study of the safety and efficacy of MIW815 (ADU-S100) administered by intratumoral injection with PDR001 to patients with advanced/metastatic solid tumors or lymphomas (IRB#49591)
Hendifar, Andrew	SCRX001-006	SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors (IRB#46520)
Klempner, Samuel	M16-438	M16-438: A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands (IRB#49976)
Klempner, Samuel	INCB24360-207	A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207) (IRB#48559)
Klempner, Samuel	TAPUR	Targeted Agent and Profiling Utilization Registry (TAPUR) Study (IRB#49119)
Limvorasak, Suwicha	ONCPHARM2017-01	ONCPHARM2017-01: Improving safety and quality of cancer care in patients receiving checkpoint inhibitors for treatment of advance malignancies (I-CARE) (IRB#50345)
Mita, Monica	BGB-A317/BGB-290	BGB-A317/BGB-290: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the anti-PD-1 Monoclonal Antibody BGB-A317 in combination with the PARP inhibitor BGB-290 in Subjects with Advanced Solid Tumors (IRB#50419)
Mita, Monica	IIT2015-20-MITA-CSMCMATCH	Personalized Cancer Care at Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute (IRB#44912)
Mita, Monica	MINNELIDE101	MINNELIDE101: A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide? Capsules given alone or in combination with Protein-Bound Paclitaxel in patients with Advanced Solid Tumors (IRB#49784)
Mita, Alain	EDO-S101-1002	EDO-S101-1002: A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients with Advanced Solid Tumors (IRB#49441)
Mita, Alain	EAY131	EAY131: Molecular Analysis for Therapy Choice (MATCH) (IRB#41419)
Mita, Monica	RGX-104-001	A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (IRB#46271)
Mita, Monica	S1609	S1609 DART: Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (IRB#47963)
Mita, Monica	BPT-201	BPT-201: A Phase 1/2, Multicenter, Single Arm, Open Label, Dose Escalation Study of Birinapant in Combination with Pembrolizumab (KEYTRUDA?) in Patients with Relapsed or Refractory Solid Tumors (IRB#50135)
Natale, Ronald	IIT2017-11-NATALE-LUNG01	IIT2017-11-NATALE-LUNG01: Biomarkers of Targeted Therapy-Induced Apoptosis and Mechanisms of Sensitivity/Resistance in Patients with Advanced Cancers (IRB#53113)
Shiao, Stephen	IIT2016-18-SHIAO-NEOADSRS	IIT2016-18-SHIAO-NEOADSRS: Neoadjuvant radiosurgery for the treatment of metastatic brain tumors (IRB#47027)

New studies open frequently, please check back for updates

The following physicians have trials which are currently recruiting patients. If you do not see the doctor you are searching for, please call 310-423-2133 for more information.

Phase I

Researchers test an experimental drug or treatment in a small group of people (20-80), to evaluate its safety and identify side effects. Often these trials are not disease specific and may include more than one type of cancer.

Phase II

The experimental drug or treatment is administered to a larger group of people (100-300) to determine its effectiveness and to further evaluate its safety.

Phase III

The experimental drug or treatment is administered to larger groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it with standard or equivalent treatment, and collect information that will allow the experimental drug or treatment to be used safely.